KPV vs AOD-9604
Side-by-side comparison of key properties, dosing, and research.
- Summary
- KPV is a naturally occurring anti-inflammatory tripeptide derived from the C-terminal of alpha-MSH. It powerfully suppresses intestinal and systemic inflammation via melanocortin receptors, making it valuable for IBD, gut healing, and wound repair.
- AOD-9604 is a modified fragment of human growth hormone (residues 177-191) with an additional tyrosine residue that significantly enhances bioavailability. Originally developed as an anti-obesity drug by Metabolic Pharmaceuticals, it stimulates lipolysis and inhibits lipogenesis without the diabetogenic effects of full GH.
- Half-Life
- Short half-life (~15–30 minutes), but effects persist longer due to receptor-level anti-inflammatory cascades
- 30-45 minutes injectable; longer with nasal spray formulation
- Admin Route
- Oral, SubQ, Topical
- SubQ, Intranasal, Oral
- Research
- —
- —
- Typical Dose
- 500 mcg – 1 mg
- 300-600 mcg
- Frequency
- Once to twice daily
- Once daily
- Key Benefits
- Reduces intestinal inflammation (IBD, Crohn's, colitis)
- Promotes gut mucosal healing and barrier integrity
- Accelerates wound healing topically
- Suppresses systemic inflammatory cytokines
- Antimicrobial properties against pathogens
- Reduces neuroinflammation when administered systemically
- May improve symptoms of inflammatory skin conditions
- Selective fat loss without anabolic side effects
- No effect on blood glucose or insulin resistance
- Improved bioavailability over Fragment 176-191
- GRAS (Generally Recognized As Safe) status in Australia
- Potential cartilage repair and anti-inflammatory properties
- Does not suppress natural GH production
- Side Effects
- Generally very well tolerated
- Mild injection site reactions (SC)
- Rare: transient flushing
- Localized injection site reactions
- Headache (rare)
- Hypoglycemia risk in combination with insulin (very rare)
- Stacks With
- —
- —